Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

Top-Thema

22:32 Uhr
ROUNDUP/Aktien New York Schluss: Erneut Bestmarken - IBM-​Zahlen treiben Dow an

MiMedx Announces Release Date for 2016 Full Year Results

Donnerstag, 16.02.2017 23:05 von

PR Newswire

MARIETTA, Ga., Feb. 16, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that its results for the fourth quarter and year ended December 31, 2016, will be released before the opening of the market on Thursday, February 23, 2017.  MiMedx will host a live broadcast of its fourth quarter and year-end conference call on Thursday, February 23, 2017, at 10:30 a.m. eastern time.  A listen-only simulcast of the MiMedx conference call will be available online at the Company's website, www.mimedx.com.  A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.  The replay can also be found on the Company's website at www.mimedx.com.

About MiMedx

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mimedx-announces-release-date-for-2016-full-year-results-300409194.html

SOURCE MiMedx Group, Inc.